Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.

Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.

It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.

From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.

Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.

As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.

By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.

KEY PEOPLE

Boaz Wachtel, Director & Co-Founder

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia’s first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland.

read more

Adam Blumenthal, Non-Executive Chairman & Co-Founder

Mr. Blumenthal has 10 years’ experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.

read more

Dr. James Ellingford, Executive Director

Dr. Ellingford’s professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.

read more

Jorge Wernli, Commercial/Market Access Director

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.

read more

Dr. Gian Trepp, Commercial/Marketing Director

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.

read more

Chris Hession, Director of Strategic Partnerships

Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region. He has held leadership positions with a number of multi-national companies and introduced several new ingredients across the APAC region over this time.

read more

Chris Grundy, Chief Financial Officer

Mr Grundy is a career CFO with over 30 years’ commercial experience in the life sciences sector, in listed and large multi- national companies as well as early-stage, rapidly-growing businesses. His ex-perience in other companies includes operational roles in pharmaceutical manufacturing and distribu-tion as CEO and in marketing. He has worked in Australia, the UK and Southern Africa. He qualified as a Chartered Accountant with Ernst & Youn

read more

Bruce Linton, Strategic Advisor

Mr. Linton is one of the world’s leading cannabis executives and an accomplished entrepreneur. He has extensive sector experience as a founder, CEO, Board member and adviser to a number of global cannabis companies.

read more

RELATED STOCKHEAD STORIES